Tetrous, Inc. has successfully closed a $6.5 million Series A financing round.
Tetrous Closes $6.5M Series A
1 min read Premium comments
#enfix#tetrous
The round was a Series A Regulation D offering available to accredited investors. The regulation allows capital to be raised through the sale of securities without having to register the securities with the SEC.
Over 50% of the raise came from strategic partners, the management team, and existing shareholders. Manufacturing and distribution partners in the U.S. and Australia participated. According to the press release, the round was “expanded twice from the initial $5,000,000 target due to overwhelming interest and support from existing investors, strategic partners and new investors.”
Tetrous CEO, serial entrepreneur and University of Illinois Engineering school alumni, Bradley Patt, Ph.D. expressed excitement about the financing round, saying, “We are thrilled with the success of this financing round and the confidence our existing shareholders and strategic partners have placed in us.”
Dr. Patt continued, “This funding is enabling us to further enhance our product offerings, broaden our reach, and continue to deliver exceptional value to our customers. It’s All About the Enthesis.”
Founded in 2019, Tetrous is a regenerative medicine company based in California. It is currently focused on developing products for enthesis repair in sports medicine applications.
Its product portfolio includes its EnFix® family of allograft products. These products were created to improve healing at the enthesis. According to the press release, this is where failure often occurs. The implants are “100% demineralized bone fiber (DBF), providing osteoinductivity and osteoconductivity, resulting in optimal biologic performance with minimal disruption to current surgical techniques.”
The Series A funds will go towards improving the company’s position in the market, generating additional clinical data for its products, and expanding the surgical applications of its technology. Per the press release, Tetrous plans to expand its applications to include “hip, knee, ankle and elbow procedures with existing and new product offerings.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.